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P02-8 Narrow-leafed lupin (Lupinus 
angustifolius L.) seed β-conglutin proteins 
induce G0/G1 arrest and apoptosis in human 
colorectal cancer cells 
J. Escudero-Feliu, M. García -Costela, S. Ríos-Arrabal, S. 
Moreno-SanJuan, JD. Puentes-Pardo, J. León , and J.C. 
Jimenez-Lopez.  
Research Unit, Instituto de Investigación Biosanitaria de 
Granada, ibs.GRANADA.  
"Introduction: Lupins seed proteins seem to be 
promising as innovative source of functional food with 
pos itive health aspects: prevention of cardiovascular 
diseases and reduction of glucose and cholesterol 
blood levels. 
Lupinus angustifolius (narrow-leafed lupin, NLL) seeds 
are a  va luable source of proteins with multiple 
nutraceutical properties. Among these proteins, 
research attention has  been focused on the β-
conglutin family.  
Recently, the potential anti-diabetic, antioxidant and 
anti -inflammatory activities of β-conglutins 1, 3 and 6 
have been s tudied (decrease of pro-inflammatory 
cytokines, inhibition of chemotaxis and cell adhesion 
capacity among others).  
Methodology: We puri fied NLL recombinant β-
conglutins (rβ1, rβ3, and rβ6) us ing affinity-
chromatography and evaluated their effects  on 
colorectal cancer (CRC) cel l l ines HCT-116 (p53 wild-
type) and HCT-116 p53 nul l (p53 inactive) by cell  
cul ture and flow cytometry assays.  
Results: The results showed that β-conglutins are 
capable of inhibiting the growth of CRC cells. In HCT-
116 cel l line, the IC50 va lues are 0.8, 5.8 and 30.1 μg 
ml  for β1, β3 and β6 respectively. Moreover, for HCT-
116 p53 nul l  line, the IC50 va lues are 3.0, 3.4 and 51.8 
μg/ml  for β1, β3 and β6 respectively. Thereby, in both 
cel l  lines, the effect is higher in the case of β1, followed 
by β3 and β6. Additionally, cell proliferation decreases, 
inducing cel l  cycle arrest independently of p53. 
Speci fically, β1 and β3 induce accumulation in G0/G1 
phase while β6 induces, in addition, accumulation in 
G2/M. In a ll cases, very few cells were found in S phase. 
Finally, this  treatment cons iderably increases the 
apoptosis independently of p53. 
Discussion: β1, β3 and β6 conglutin proteins from NLL 
seeds affect the viability in CRC cel ls at very low 
concentrations, inducing apoptosis and decreasing cell 
prol iferation by cell cycle arrest: these proteins may be 
natural chemotherapeutic agents with potential uses 
for treatment of human CRC. 
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Controlled Doxorubicin Delivery to Cancer Cells
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The use of mesoporous s i lica nanoparticles with 
“molecular gates” to specifically deliver therapeutic 
payloads to cancer cells, among other target destinies, 
has  been successfully proved in the past due to their 
wel l-known benefits1. Nevertheless, their 
displacement to the target i s  only provoked by the 
passive EPR effect, resulting in poor tumor penetration 
and deficient cytotoxic results. For this reason, have 
recently emerged the development of self-propelled 
nanodevices to improve the tumor reach an 
infiltration, named as nanomotors. However, most of 
the nanomotors reported present a  dichotomy 
between velocity and biocompatibility, to achieve high 
speeds they need to use toxic exogenous fuels 2-4. 
Therefore, in this  work we report the des ign and 
evaluation of a  novel multifunctional nanomotor with 
potential “smart” anticancerogenic properties. Consist 
in a  Janus nanodevice, presenting two differentiate 
faces: a  platinum nanoparticle (Pt NP) and a  
mesoporous silica nanoparticle (MSN). The MSN part 
acts  as  a  nanocontainer, being loaded with an 
anticancer drug (Doxorubicin). Externally is  
functionalized by amide bonds with the high active 
enzyme Glucose Oxidase (GOx), acting at the same 
time as  “molecular gate” and fi rs t s tep propelling 
system, transforming glucose into hydrogen peroxide 
(H2O2). Whi le the Pt NP gives  the final pushing to the 
nanomotor, cata lyzing the reduction of H2O2 into 
water and oxygen (gas). The advantages of our Janus 
Pt-MSN-Doxo-GOx nanomotor res ide in the 
bioavailability of the fuel , glucose, in the tumor 
microenvironment and in i ts anisotropy, that guide 
their spatial tra jectories in a  directional manner.  
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INTRODUCTION:
• Lupins seed proteins seem to produce promising positive health
aspects, preventing cardiovascular disease, and reduction of
glucose and cholesterol blood levels.
• Among these proteins, particular research attention has been
focused to those from the vicilin or beta-conglutin family, which are
the most abundant proteins in NLL seeds.
• Recently, we have demonstrated the potential antidiabetic,
antioxidant and anti-inflammatory activities of particular beta-
conglutin proteins β1, β3 and β6: decrease of the production of
pro-inflammatory cytokines; inhibition of chemotaxis and cell
adhesion capacity. These properties could be attributed to the
ability of these conglutins to interact with insulin.
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MATERIALS AND METHODS: In the present study, we purified NLL
recombinant betaconglutin proteins (rβ1, rβ3, and rβ6) using affinity–
chromatography (Figure 1) and evaluated their effects on colon cancer
cell lines HCT-116 (p53 wild-type), and HCT-116 p53 null (p53 inactive)
using flow cytometry and tetrazolium (MTT) assay for cellular viability
and activity (Figures 2 and 3).
REFERENCES: C. Delgado-Andrade, R. Olías, J.C. Jimenez-Lopez, A. Clemente. Arbor 2016, 192, a313- ; R.C. 
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CONCLUSIONS: In summary, β-conglutin proteins from blue
lupine seeds, affect the viability in colorectal cancer cells, inducing
apoptosis and decreasing cell proliferation by cell cycle arrest,
either in G0/G1 phase or in G2/M phase. Therefore, our results
suggest that NLL β-conglutin proteins may be potential
chemotherapeutic agents with potential uses for treatment of
human colon cancer.
RESULTS:
• β1, β3 and β6 conglutins are capable of inhibiting the growth of
colorectal cancer cells.
• When the HCT-116 p53 null line is treated, the IC50 values are 3.0,
3.4 and 51.8μg/ml for β1, β3 and β6 conglutin, respectively (figure 2).
• In both cell lines β-conglutin proteins effect is higher in the case of
β1, followed by β3 and β6.
• β1 and β3 conglutins induce accumulation in G0/G1 phase, while β6
induces, in addition, the accumulation in G2/M phase (figure 3A).
• On the other hand, the treatment with the three conglutins
considerably increases the apoptosis, independently of p53 (figure
3B).
Figure 1. Overexpression, purification and selection of recombinant β-conglutins using affinity chromatography
and western-blotting. A: Overexpression of β-conglutins using E.Coli Rosetta.
B: Purification with Affinity-Chromatography and dialysis. C: Checking of β-conglutins with Western Blotting.
Figure 2. Results of the tetrazolium (MTT) assay for cellular viability for HCT-116 and HCT-116 p53 null cell lines. For
both cell lines, the 24h treatment with the three β-conglutin proteins produces a decrease in the cellular viability
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Figure 3. Results of flow cytometry assays for HCT-116 and HCT-116 p53 null cell lines with a control (Vh) without
treatment and three 24h treatments with β-conglutins 1, 3 and 6. A: Decrease of cell proliferation by cell cycle arrest
in G0/G1 or G2/M phase. B: β-conglutins induce apoptosis in colorectal cancer cells.
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